Lipocine (LPCN) Stock Price, News & Analysis

Company Overview

Lipocine Inc. is a biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and clinical performance of active pharmaceutical ingredients that may otherwise have limited effectiveness when taken orally.

Lipocine’s lead product is Tlando, an oral testosterone replacement therapy containing testosterone undecanoate. The U.S. Food and Drug Administration approved Tlando in 2022 for testosterone replacement therapy in adult males with hypogonadism associated with an underlying medical condition. The product was designed to provide an oral alternative to injectable, topical and other testosterone replacement treatments.

In addition to Tlando, Lipocine has pursued a pipeline of product candidates targeting areas such as central nervous system disorders, metabolic conditions and other diseases. The company is headquartered in Salt Lake City, Utah, and its development and commercialization activities have primarily focused on the United States, while its drug-delivery platform may support partnerships or licensing opportunities in other markets.

Key Stats

• Today's Range: $1.42 to $1.50
• 50-Day Range: $1.44 to $2.45
• 52-Week Range: $1.40 to $12.37
• Volume: 111,986 shs
• Average Volume: 5.68 million shs
• Market Capitalization: $11.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Lipocine Stock Analysis - MarketRank™

Lipocine scored higher than 78% of companies evaluated by MarketBeat, and ranked 113th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Lipocine has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Lipocine has a consensus price target of $4.00, representing about 177.8% upside from its current price of $1.44.

Amount of Analyst Coverage

Lipocine has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lipocine are expected to grow in the coming year, from ($1.54) to ($1.03) per share.

Price to Book Value per Share Ratio

Lipocine has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.47% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 0.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently increased by 259.28%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipocine does not currently pay a dividend.

Dividend Growth

Lipocine does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.26

News Sentiment

Lipocine has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Lipocine this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lipocine to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $82,174.00 in company stock, which represents 0.6925% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $82,174.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

4.69% of the stock of Lipocine is held by insiders.

Percentage Held by Institutions

9.11% of the stock of Lipocine is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/30/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LPCN
• CIK: 1535955
• Web: www.lipocine.com
• Phone: (801) 994-7383
• Fax: 801-994-7388
• Employees: 14
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Lipocine: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +177.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.63 million
• Net Margins: -755.39%
• Pretax Margin: -755.26%
• Return on Equity: -64.75%
• Return on Assets: -57.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.48
• Quick Ratio: 11.48

Sales & Book Value

• Annual Sales: $1.98 million
• Price / Sales: 5.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 8,240,000
• Free Float: 7,857,000
• Market Cap: $11.87 million
• Optionable: No Data
• Beta: 0.40